CMS Advisory Panel Provides Some Potential Good News For Glaukos
Rate adjustment recommendations to US Medicare could result in less drastic reimbursement cuts for Glaukos than those currently on the table.
You may also be interested in...
The US Medicare agency's new rule for facility fees brings more bad news for Glaukos; Wells Fargo downgrades company’s stock in response.
The US Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that includes new reimbursement levels for multiple medical devices, including the Glaukos iStent.
A bipartisan group of legislators in the US House of Representatives wants to stop the Centers for Medicare & Medicaid Services (CMS) from finalizing proposed cuts to treatments for cancer, kidney failure, artery disease and other conditions.